WALTHAM, Mass., Aug. 22, 2022 (GLOBE NEWSWIRE) -- DynamiCure, a private biopharmaceutical company translating pioneering immuno-normalization insights into a pipeline of innovative therapeutic ...
WALTHAM, Mass., Sept. 20, 2022 (GLOBE NEWSWIRE) -- DynamiCure, a private biopharmaceutical company translating pioneering immuno-normalization insights into a pipeline of innovative therapeutic ...
SUWON, South Korea--(BUSINESS WIRE)--OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, announced today that the Company signed a memorandum of understanding (MOU) ...
Los Angeles, California, USA, November 15, 2022 – ImaginAb Inc., a global biotechnology company focused on developing 89Zr crefmirlimab berdoxam (CD8 ImmunoPET TM) imaging agent and ...
Phase 1 trial aims to assess the safety and anti-tumor activity of the candidate in dose-escalation and dose-expansion phases of the study WALTHAM, Mass., Nov. 08, 2022 (GLOBE NEWSWIRE) -- DynamiCure, ...
Article ‘Count’ and ‘Share’ for Dynamique Microbienne associée aux Infections Urinaires et Respiratoires (DynaMicURe) based on listed parameters only. The articles listed below published by authors ...
OliX participated in the ‘Korea-US Digital·BioHealth Business Forum’ hosted by the South Korean Ministry of Health and Welfare and Korea Health Industry Development Institute. The Company signed an ...
LOS ANGELES, Nov. 15, 2022 /PRNewswire/ -- ImaginAb Inc., a global biotechnology company focused on developing 89Zr crefmirlimab berdoxam (CD8 ImmunoPET™) imaging agent and radiopharmaceutical therapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results